Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer (NCT07613151) | Clinical Trial Compass
RecruitingNot Applicable
Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer
Italy250 participantsStarted 2026-05-01
Plain-language summary
The NAPOLI Study is a retrospective multicenter observational study designed to characterize negative hormone receptor and apocrine lobular invasive breast cancer. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female or male patients aged ≥18 years.
* Histologically confirmed invasive lobular carcinoma of the breast.
* Presence of apocrine differentiation/features documented in pathology report or confirmed by local pathology review.
* Negative hormone receptors.
* Diagnosis and/or treatment at one of the participating centers.
* Availability of essential clinicopathological data.
* Availability of follow-up data, when applicable.
Exclusion Criteria:
* Pure ductal carcinoma without lobular invasive component.
* Metastatic tumor to the breast from non-breast primary cancer.
* Insufficient pathological documentation to confirm eligibility.
* Missing essential clinical data.
* Patients who denied consent for retrospective data use, where applicable by local regulations.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Clinicopathological characterization of apocrine invasive lobular breast carcinoma
Timeframe: Through study completion, an average of 5 years